Saturday, March 31, 2018 11:20:52 AM
Meanwhile a PR campaign logically should initiate. Tell us about manufacturing, U of Maryland success, GSA and government sales beginning; incremental revenues and retail rollout plans.
Hopefully tell us about funding package to get phase 2 clinicals rolling for MS pediatric. Tell us if you plan to pursue government grants and funding that is coming available to fight opiods. These funds could be all that is needed to strengthen Nyloxin case as a significant tool to fight pain, etc..
Nobody is denying the product, nor the potential. We just need a methodical structured approach and watch market valuations quickly rise to 20,30,50 million as success is achieved. Whether there is 2,2.5, or 3 Billion shares out won’t matter much as the stock surpasses .01 and sales and clinical pipelines have momentum. Optimism will be high and 100 or 200 million valuations will seem and realistically be more achievable in the following year..
Everyone wins: the company, the financiers, shareholders and most importantly the people who desperately need real solutions to medical issues.
Be methodical.. be patient.. be successful..
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM